WuXi PharmaTech (Cayman) Inc., a pharmaceutical, biotechnology, and medical device R&D services company with operations in China and the United States, reports that its manufacturing subsidiary, Syn-The-All Pharmaceuticals Co., Ltd., has begun construction of a new R&D and cGMP manufacturing site in Changzhou, about 110 miles west of Shanghai. 

The new campus will be constructed in phases and include both research manufacturing and commercial manufacturing facilities.  Facilities constructed in Phase 1 will double the company’s current manufacturing capacity and be operational by the fourth quarter of 2015. Upon completion of the entire project, the site will triple current capacity and have the capacity to house more than 1,500 employees, including chemists, production staff, and supporting staff,. 

Source: Wuxi PharmaTech